Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3520 Target Snapshot

Envelope glycoprotein gp160 · SINGLE PROTEIN · Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)

Back to Search Search this target Browse approvals Evidence Card
145Compounds
31Assays
0Approved Drugs
326.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Envelope glycoprotein gp160 shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P04578. Start with HIV infection, then reuse UniProt P04578 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with HIV infection, then reuse UniProt P04578 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
HIV infection

Envelope glycoprotein gp160 shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include F105, FOSTEMSAVIR, FOSTEMSAVIR TROMETHAMINE, KD-247. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Envelope glycoprotein gp160 as ChEMBL target CHEMBL3520, mapped to UniProt P04578. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Envelope glycoprotein gp160
SINGLE PROTEIN · Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
As of 2026-09-13
ChEMBL target ID
CHEMBL3520
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04578
Envelope glycoprotein gp160
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Envelope glycoprotein gp160 is the right protein anchor across sources, using UniProt P04578 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why HIV infection is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEnvelope glycoprotein gp160
Target TypeSINGLE PROTEIN
OrganismHuman immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
UniProtP04578
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEnvelope glycoprotein gp160
UniProt AccessionP04578
Component TypeProtein
Sequence Length856 aa

Envelope glycoprotein gp160

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Envelope glycoprotein gp160, mapped to UniProt P04578. Sequence length is 856 aa.

Mapped IDP04578
Review nameEnvelope glycoprotein gp160
OrganismHuman immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Envelope glycoprotein gp160 shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block.

Approved-linked Approved
HIV infection
4 linked drugs · 4 direct · 4 efficacy
Linked drugF105
Linked drugFOSTEMSAVIR
Linked drugFOSTEMSAVIR TROMETHAMINE
Linked drugKD-247
Approved-linked Approved
HIV-1 infection
2 linked drugs · 2 direct · 2 efficacy
Linked drugFOSTEMSAVIR
Linked drugFOSTEMSAVIR TROMETHAMINE
Approved-linked Approved
immunodeficiency disease
1 linked drug · 1 direct · 1 efficacy
Linked drugFOSTEMSAVIR TROMETHAMINE
Approved-linked Approved
viral disease
1 linked drug · 1 direct · 1 efficacy
Linked drugFOSTEMSAVIR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include F105, FOSTEMSAVIR, FOSTEMSAVIR TROMETHAMINE, KD-247. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseHIV infection
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50324.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3600949 9.47 IC50 0.34 Preclinical
CHEMBL529902 9.46 IC50 0.35 Preclinical
CHEMBL3600950 9.36 IC50 0.44 Preclinical
CHEMBL1242210 9.25 IC50 0.56 Preclinical
CHEMBL428607 9.08 IC50 0.84 Preclinical
CHEMBL411406 9.07 IC50 0.86 Preclinical
CHEMBL3600952 8.66 IC50 2.18 Preclinical
CHEMBL3600951 8.64 IC50 2.27 Preclinical
CHEMBL2029048 7.94 Kd 11.4 Preclinical
CHEMBL3600953 7.75 IC50 17.74 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
0
5.5
0
6.0
0
6.5
3
7.0
3
7.5
0
8.0
5
8.5
6
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

31
Total Assays
20
Tested Compounds
2
Assay Types
Binding — 27 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 15 6 5.8
cell-based format 12 14 7.5
Functional — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine